Literature DB >> 12877785

A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China.

Wei Wu1, Jingfeng Wang, Pinming Liu, Weixian Chen, Songmei Yin, Shanping Jiang, Li Yan, Jun Zhan, Xilong Chen, Jianguo Li, Zitong Huang, Hongzhang Huang.   

Abstract

OBJECTIVE: To describe a hospital outbreak of severe acute respiratory syndrome (SARS) and summarize its clinical features and therapeutic approaches.
METHODS: The outbreak started with a SARS patient from the community, and a total of 96 people (76 women and 20 men, mean age (29.5 +/- 10.3) years, 93.8% of whom were health care workers) who had exposure to this source patient became infected in a short time. Clinical data in this cohort were collected prospectively as they were identified.
RESULTS: (1) The incubation period ranged from 1 to 20 (mean: 5.9 +/- 3.5) days. The duration of hospitalization was (17.2 +/- 8.0) days. (2) The initial temperature was (38.3 +/- 0.6) degrees C, while the highest was (39.2 +/- 0.6) degrees C (P < 0.001), with fever duration of (9.0 +/- 4.2) days. (3) Other most common symptoms included fatigue (93.8%), cough (85.4%), mild sputum production (66.7%), chills (55.2%), headache (39.6%), general malaise (35.4%) and myalgia (21.9%). (4) The radiographic changes were predominantly bilateral in the middle or lower lung zones. The number of affected lung fields was 1.2 +/- 0.8 on presentation, which increased to 2.9 +/- 1.4 after admission (P < 0.001). The interval from the beginning of fever to the onset of abnormal chest radiographs was (3.5 +/- 2.3) days, which increased in size, extent, and severity to the maximum (6.7 +/- 3.5) days later. The time before the lung opacities were basically absorbed was (14.9 +/- 7.8) days. (5) Leukopenia was observed in 67.7% of this cohort. The time between the onset of fever and leukopenia was (4.4 +/- 2.3) days, with the lowest white blood cell count of (2.80 +/- 0.72) x 10(9)/L. (6) The lowest arterial oxygen saturation was (94.8 +/- 3.1)% with supplementary oxygen. (7) Antibiotical therapies included tetracyclines (91.0%), aminoglycosides (83.3%), quinolones (79.2%); 18.8% of the patients received a combination of tetracyclines and aminoglycosides, while 11.5% received a combination of tetracyclines and quinolones, and 63.5% received a combination of tetracyclines, aminoglycosides and quinolones. Vancomycin was used in 13.5% of the patients. (8) 68.8% of the patients were treated with methylprednisolones for a mean interval of (4.9 +/- 2.4) days. The initial dose was (67.3 +/- 28.2) mg/d and the maximal dose was (82.4 +/- 30.5) mg/d. (9) Human gamma-globulin, interferon-alpha, antiviral drugs (oral ribavirin or oseltamivir) were used respectively in 68.6%, 46.9% and 92.7% of the patients. (10) Ninety-five patients (99.0%) had a complete clinical recovery, and only 1 patient (1.0%) died.
CONCLUSIONS: SARS appears to be quickly infectious and potentially lethal among health care workers, characterized by acute onset and rapid progression, and mostly bilateral lung involvement on chest radiographs. Proper administration of glucocorticosteroids seems to be of some benefits. Antibiotics, human gamma-globulin, interferon-alpha, and antiviral drugs, although empirically, might be useful to shorten the clinical course.

Entities:  

Mesh:

Year:  2003        PMID: 12877785

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  16 in total

1.  Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice.

Authors:  Nadine De Albuquerque; Ehtesham Baig; Xuezhong Ma; Jianhua Zhang; William He; Andrea Rowe; Marlena Habal; Mingfeng Liu; Itay Shalev; Gregory P Downey; Reginald Gorczynski; Jagdish Butany; Julian Leibowitz; Susan R Weiss; Ian D McGilvray; M James Phillips; Eleanor N Fish; Gary A Levy
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

Review 2.  Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.

Authors:  Kiarash Saleki; Shakila Yaribash; Mohammad Banazadeh; Ehsan Hajihosseinlou; Mahdi Gouravani; Amene Saghazadeh; Nima Rezaei
Journal:  Eur J Pharmacol       Date:  2021-06-12       Impact factor: 4.432

3.  Management of Critically Ill Patients with Severe Acute Respiratory Syndrome (SARS).

Authors:  Arthur Chun-Wing Lau; Loretta Yin-Chun Yam; Loletta Kit-Ying So
Journal:  Int J Med Sci       Date:  2004-03-10       Impact factor: 3.738

4.  Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: An updated critical systematic review and meta-analysis.

Authors:  Chengjun Yu; Lian Kang; Jiadong Chen; Na Zang
Journal:  Int Immunopharmacol       Date:  2020-06-25       Impact factor: 4.932

Review 5.  Treatment of severe acute respiratory syndrome.

Authors:  S T Lai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-09       Impact factor: 3.267

6.  The emerging utility of neopterin?

Authors:  John Beigel
Journal:  Clin Immunol       Date:  2005-07       Impact factor: 3.969

7.  Understanding the spatial diffusion process of severe acute respiratory syndrome in Beijing.

Authors:  B Meng; J Wang; J Liu; J Wu; E Zhong
Journal:  Public Health       Date:  2005-10-07       Impact factor: 2.427

Review 8.  A review of treatment modalities for Middle East Respiratory Syndrome.

Authors:  Yin Mo; Dale Fisher
Journal:  J Antimicrob Chemother       Date:  2016-09-01       Impact factor: 5.790

9.  Nosocomial Transmission of SARS.

Authors:  Nelson Lee; Joseph J.Y. Sung
Journal:  Curr Infect Dis Rep       Date:  2003-12       Impact factor: 3.725

Review 10.  SARS: ventilatory and intensive care.

Authors:  Loretta Y C Yam; Rong Chang Chen; Nan Shan Zhong
Journal:  Respirology       Date:  2003-11       Impact factor: 6.424

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.